Syed Zaidi, MD
Addiction Psychiatry · Pinellas Park, FLNPI 1225242647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,855, 6.2 times the $463 reported in 2022.
Across 257 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$906
- Neurocrine Biosciences, Inc.$754
- Alkermes, Inc.$658
- Teva Pharmaceuticals USA, Inc.$493
- Otsuka America Pharmaceutical, Inc.$454
- Supernus Pharmaceuticals, Inc.$440
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,447100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $906 |
| Neurocrine Biosciences, Inc. | 27 | $754 |
| Alkermes, Inc. | 31 | $658 |
| Teva Pharmaceuticals USA, Inc. | 30 | $493 |
| Otsuka America Pharmaceutical, Inc. | 21 | $454 |
| Supernus Pharmaceuticals, Inc. | 21 | $440 |
| Johnson & Johnson | 15 | $398 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $366 |
| Indivior Inc. | 15 | $308 |
| E.r. Squibb & Sons, L.L.C. | 13 | $236 |
| Lundbeck LLC | 6 | $120 |
| Idorsia Pharmaceuticals US Inc | 6 | $112 |
| Lilly USA, LLC | 1 | $35 |
| TMS Neurohealth Centers Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,455 in reported general payments places this provider in the 75th percentile of 29 addiction psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 22 | $227,326 |
| Invega SustennaPaliperidone Palmitate | 55 | $179,250 |
| IngrezzaValbenazine Tosylate | 20 | $165,327 |
| Austedo XrDeutetrabenazine | 18 | $126,945 |
| AustedoDeutetrabenazine | 22 | $124,286 |
| VraylarCariprazine Hcl | 43 | $62,608 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $52,853 |
| RexultiBrexpiprazole | 23 | $34,100 |
| Aripiprazole | 283 | $27,677 |
| Olanzapine | 484 | $19,507 |
| BelsomraSuvorexant | 25 | $11,026 |
| Atomoxetine Hcl | 58 | $10,775 |
| Effexor XrVenlafaxine Hcl | 12 | $6,749 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $4,769 |
| Clozapine | 37 | $4,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $398 | $406,57677 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $493 | $251,23140 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $754 | $165,32720 claims |
| AbbVieVraylar | $906 | $62,60843 claims |
| Alkermes, Inc.Lybalvi | $658 | $52,85331 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $454 | $34,10023 claims |
| Lilly USA, LLCOlanzapine | $35 | $19,507484 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 addiction psychiatry providers in Florida.
Other addiction psychiatry in Pinellas Park
- Raul RodriguezDelray Beach$31K
- Jason FieldsNew Port Richey$26K
- Edward BariasJupiter$21K
- Mary SheehanTampa$16K
- Aldo MoralesFort Lauderdale$13K
- Krishan BatraOdessa$10K
- Lawrence WeinsteinSt Petersburg$6K
- Vincence DillonPensacola$2K
- Curtis PhillipsDelray Beach$2K
- Zaheer AslamFort Myers$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.